Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via — Annovis Bio Inc. (NYSE: ANVS) today announces its placement in an editorial published by ("NNW"), one of 60+ brands within the @ (), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
To view the full publication, “Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition,” please visit:
Alzheimer’s disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (FDA) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer's.
However, there is no molecule or a combination of molecules that enhance cognitive functions. Thanks to innovative approaches by companies such as Annovis Bio Inc., there is reason to be optimistic about potential future breakthroughs in the AD space. Annovis has completed early research with compelling results utilizing its lead drug, buntanetap, in combination with popular drugs approved for other indications.
About Annovis Bio Inc.
Annovis Bio, headquartered in Malvern, Pennsylvania, is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.
For more information, about the company, please visit .
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at
About NetworkNewsWire
(“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the @ that delivers: (1) access to a vast network of wire solutions via to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and ; (3) to ensure maximum impact; (4) via IBN to millions of social media followers; and (5) a full array of tailored . With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished:
NetworkNewsWire
New York, NY
212.418.1217 Office
NetworkNewsWire is powered by
